Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3
JNCI Cancer Spectrum · 31.10.2023 · 7 (6)
DOI: 10.1093/jncics/pkad101 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.11.2023. Verfasst von Kei Kawana und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GLOVACC Co Ltd, Japan Agency for Medical and Development (AMED).
Abstract (Originalsprache)
Background
Although many human papillomavirus (HPV)–targeted therapeutic vaccines have been examined for efficacy in clinical trials, none have been translated into clinical use. These previous agents were mostly administered by intramuscular or subcutaneous injection to induce systemic immunity. We investigated the safety and therapeutic efficacy of an HPV-16 E7-expressing lacticaseibacillus-based oral vaccine.
Methods
In a double-blind, placebo-controlled, randomized trial, a total of 165 patients with HPV-16–positive high-grade cervical intraepithelial neoplasia 2 and 3 were assigned to orally administered placebo or low, intermediate, or high doses of IGMKK16E7 (lacticaseibacillus paracasei expressing cell surface, full-length HPV-16 E7). In the 4 groups, IGMKK16E7 or placebo was administered orally at weeks 1, 2, 4, and 8 postenrollment. The primary outcomes included histopathological regression and IGMKK16E7 safety.
Results
In per-protocol analyses, histopathological regression to normal (complete response) occurred in 13 (31.7%) of 41 high-dose recipients and in 5 (12.5%) of 40 placebo recipients (rate difference = 19.2, 95% confidence interval [CI] = 0.5 to 37.8). In patients positive for HPV-16 only, the clinical response rate was 40.0% (12 of 30) in high-dose recipients and 11.5% (3 of 26) in recipients of placebo (rate difference = 28.5, 95% CI = 4.3 to 50.0). There was no difference in adverse events that occurred in the high-dose and placebo groups (P = .83). The number of HPV-16 E7–specific interferon-γ producing cells within peripheral blood increased with level of response (stable disease, partial, and complete responses; P = .004). The regression to normal (complete response) rates among recipients with high levels of immune response were increased in a dose-dependent manner.
Conclusion
This trial demonstrates safety of IGMKK16E7 and its efficacy against HPV-16–positive cervical intraepithelial neoplasia 2 and 3. IGMKK16E7 is the first oral immunotherapeutic vaccine to show antineoplastic effects. Trial registration jRCT2031190034.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
- Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
- Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
ORCID-Profile: Kei Kawana, Takashi Iwata, Daisuke Aoki
Förderung
- GLOVACC Co Ltd
- Japan Agency for Medical and Development (AMED)
Zitieren
APA
Kawana, K., Kobayashi, O., Ikeda, Y., Yahata, H., Iwata, T., Satoh, T., Akiyama, A., Maeda, D., Hori-Hirose, Y., Uemura, Y., Nakayama-Hosoya, K., Katoh, K., Katoh, Y., Nakajima, T., Taguchi, A., Komatsu, A., Asai-Sato, M., Tomita, N., Kato, K., …, & Schust, D. J. (2023). Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3. JNCI Cancer Spectrum, 7(6). https://doi.org/10.1093/jncics/pkad101
Vancouver
Kawana K, Kobayashi O, Ikeda Y, Yahata H, Iwata T, Satoh T, et al. Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3. JNCI Cancer Spectrum. 2023;7(6). doi:10.1093/jncics/pkad101
BibTeX
@article{Kawana2023,
author = {Kawana, Kei and Kobayashi, Osamu and Ikeda, Yuji and Yahata, Hideaki and Iwata, Takashi and Satoh, Toyomi and Akiyama, Azusa and Maeda, Daichi and Hori-Hirose, Yumiko and Uemura, Yukari and Nakayama-Hosoya, Kaori and Katoh, Kanoko and Katoh, Yuki and Nakajima, Takahiro and Taguchi, Ayumi and Komatsu, Atsushi and Asai-Sato, Mikiko and Tomita, Naoko and Kato, Kiyoko and Aoki, Daisuke and Igimi, Shizunobu and Kawana-Tachikawa, Ai and Schust, Danny J},
title = {Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3},
journal = {JNCI Cancer Spectrum},
year = {2023},
volume = {7},
number = {6},
doi = {10.1093/jncics/pkad101}
}
EUVIMED